Nano siRNA - Medesis Pharma
Alternative Names: Nano-siRNA Huntington's diseaseLatest Information Update: 01 Mar 2024
At a glance
- Originator Medesis Pharma
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Huntington's disease
Most Recent Events
- 11 Jan 2024 Preclinical trials in Huntington's disease in France (Buccal) (Medesis Pharma pipeline, January 2024)